WO2007119029A3 - Co-cristaux de calixarenes et de molecules biologiquement actives - Google Patents

Co-cristaux de calixarenes et de molecules biologiquement actives Download PDF

Info

Publication number
WO2007119029A3
WO2007119029A3 PCT/FR2007/051129 FR2007051129W WO2007119029A3 WO 2007119029 A3 WO2007119029 A3 WO 2007119029A3 FR 2007051129 W FR2007051129 W FR 2007051129W WO 2007119029 A3 WO2007119029 A3 WO 2007119029A3
Authority
WO
WIPO (PCT)
Prior art keywords
crystals
biologically active
calixarenes
active molecules
molecule
Prior art date
Application number
PCT/FR2007/051129
Other languages
English (en)
Other versions
WO2007119029A8 (fr
WO2007119029A2 (fr
Inventor
Anthony William Coleman
Adina Nicoleta Lazar
Kinga Suwinska
Oksana Danylyuk
Original Assignee
Univ Claude Bernard Lyon
Inst Of Physical Chemistry Pol
Anthony William Coleman
Adina Nicoleta Lazar
Kinga Suwinska
Oksana Danylyuk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Claude Bernard Lyon, Inst Of Physical Chemistry Pol, Anthony William Coleman, Adina Nicoleta Lazar, Kinga Suwinska, Oksana Danylyuk filed Critical Univ Claude Bernard Lyon
Priority to CA002650534A priority Critical patent/CA2650534A1/fr
Priority to EP07731905A priority patent/EP2010163A2/fr
Priority to US12/226,418 priority patent/US20090233941A1/en
Publication of WO2007119029A2 publication Critical patent/WO2007119029A2/fr
Publication of WO2007119029A3 publication Critical patent/WO2007119029A3/fr
Publication of WO2007119029A8 publication Critical patent/WO2007119029A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C07C279/265—X and Y being nitrogen atoms, i.e. biguanides containing two or more biguanide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/41—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
    • C07C309/43—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton having at least one of the sulfo groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/54—Ortho- or ortho- and peri-condensed systems containing more than five condensed rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des co-cristaux d'au moins une molécule de calix[n]arène ou d'au moins un de ses dérivés, et d'au moins une molécule biologiquement active, des compositions et des médicaments les comprenant, l'utilisation de ces co-cristaux et des procédés permettant de les obtenir.
PCT/FR2007/051129 2006-04-18 2007-04-18 Co-cristaux de calixarenes et de molecules biologiquement actives WO2007119029A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002650534A CA2650534A1 (fr) 2006-04-18 2007-04-18 Co-cristaux de calixarenes et de molecules biologiquement actives
EP07731905A EP2010163A2 (fr) 2006-04-18 2007-04-18 Co-cristaux de calixarenes et de molecules biologiquement actives
US12/226,418 US20090233941A1 (en) 2006-04-18 2007-04-18 Co-Crystals of Calixarenes and Biologically Active Molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0603405A FR2899814B1 (fr) 2006-04-18 2006-04-18 Co-cristaux de calixarenes et de molecules biologiquement actives
FR0603405 2006-04-18

Publications (3)

Publication Number Publication Date
WO2007119029A2 WO2007119029A2 (fr) 2007-10-25
WO2007119029A3 true WO2007119029A3 (fr) 2007-12-21
WO2007119029A8 WO2007119029A8 (fr) 2008-03-06

Family

ID=37592458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/051129 WO2007119029A2 (fr) 2006-04-18 2007-04-18 Co-cristaux de calixarenes et de molecules biologiquement actives

Country Status (5)

Country Link
US (1) US20090233941A1 (fr)
EP (1) EP2010163A2 (fr)
CA (1) CA2650534A1 (fr)
FR (1) FR2899814B1 (fr)
WO (1) WO2007119029A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2939666B1 (fr) 2008-12-17 2012-11-30 Irsn Formulations cosmetiques et pharmaceutiques de molecules de calix[6]arenes
FR2944105B1 (fr) * 2009-04-06 2011-06-17 Centre Nat Rech Scient Addifif pour la cristallisation de proteines, utilisation et procede
ES2360027B1 (es) * 2009-11-19 2012-02-24 Universidad De Santiago De Compostela Vesiculas liofilizables sin crioprotector
GB201604639D0 (en) 2016-03-18 2016-05-04 Univ London Queen Mary Chlorhexidine crystal forms and uses thereof in medicine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999016734A1 (fr) * 1997-10-01 1999-04-08 Macgillivray Leonard R Ensemble moleculaire spherique
WO2001012177A1 (fr) * 1999-08-12 2001-02-22 Atwood Jerry L Formation de structures a l'echelle nanometrique
WO2004064762A2 (fr) * 2003-01-21 2004-08-05 S.S.C.I. Inc. Nouvelle co-cristallisation
US20050084535A1 (en) * 2001-09-17 2005-04-21 Anthony Coleman Novel calixarene based dispersible colloidal systems in the form of nanoparticles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6519335B1 (en) * 1999-04-08 2003-02-11 Lucent Technologies Inc. Apparatus, method and system for personal telecommunication incoming call screening and alerting for call waiting applications
US6832203B1 (en) * 1999-11-05 2004-12-14 Cim, Ltd. Skills based contact routing
US7050566B2 (en) * 2003-06-13 2006-05-23 Assurant, Inc. Call processing system
US8000989B1 (en) * 2004-03-31 2011-08-16 Avaya Inc. Using true value in routing work items to resources
US8234141B1 (en) * 2004-09-27 2012-07-31 Avaya Inc. Dynamic work assignment strategies based on multiple aspects of agent proficiency
US7995717B2 (en) * 2005-05-18 2011-08-09 Mattersight Corporation Method and system for analyzing separated voice data of a telephonic communication between a customer and a contact center by applying a psychological behavioral model thereto
US8065192B2 (en) * 2006-09-14 2011-11-22 Boundless Network Method and system for tiered pricing of customized base products
US8259924B2 (en) * 2009-09-21 2012-09-04 Genesys Telecommunications Laboratories, Inc. System for creation and dynamic management of incoming interactions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999016734A1 (fr) * 1997-10-01 1999-04-08 Macgillivray Leonard R Ensemble moleculaire spherique
WO2001012177A1 (fr) * 1999-08-12 2001-02-22 Atwood Jerry L Formation de structures a l'echelle nanometrique
US20050084535A1 (en) * 2001-09-17 2005-04-21 Anthony Coleman Novel calixarene based dispersible colloidal systems in the form of nanoparticles
WO2004064762A2 (fr) * 2003-01-21 2004-08-05 S.S.C.I. Inc. Nouvelle co-cristallisation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Directory Listing for /documents/ -Up To", Retrieved from the Internet <URL:http://www.ices.a-star.edu.sg/ices/documents/> [retrieved on 20070116] *
ALSHAHATEET S; LAU E H E; ONG TIEN TENG, CHOW PUI SHAN A; TAN R B H: "Crystal Engineering of Pharmaceutical Co-crystals and Nanocapsules: Novel approaches to improve the physical properties and bioavailability of active pharmaceutical ingredients", 2005, XP002414928, Retrieved from the Internet <URL:http://www.ices.a-star.edu.sg/ices/research_and_development/crystal_engineering.do;jsessionid=EF34EBD1599008664FAC470FB359B6B9> [retrieved on 20070115] *
ALSHATEET S; TIEN TENG ONG; CHOW PUI SHAN A; TAN R B H: "Crystal Engineering of Pharmaceutical Co-crystals and calix[4]arenes: Novel apporaches to improve the physical properties and bioavailability of active pharmaceutical ingredients", 2005, XP002414929, Retrieved from the Internet <URL:http://www.ices.a-star.edu.sg/ices/documents/web-highlight-solhe-sep05.pdf> [retrieved on 20070115] *
BEN SALEM A ET AL: "Synthesis and characterisation of a new podand based on a calixarene and a beta-lactam", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 42, no. 40, 1 October 2001 (2001-10-01), pages 7033 - 7036, XP004317885, ISSN: 0040-4039 *
SILVA DA E ET AL: "BIOPHARMACEUTICAL APPLICATIONS OF CALIXARENES", SCIENCES TECHNIQUES ET PRATIQUES STP PHARMA SCIENCES, PARIS, FR, vol. 14, no. 1, 2004, pages 3 - 20, XP008036113, ISSN: 1157-1489 *

Also Published As

Publication number Publication date
EP2010163A2 (fr) 2009-01-07
FR2899814B1 (fr) 2008-09-12
FR2899814A1 (fr) 2007-10-19
WO2007119029A8 (fr) 2008-03-06
CA2650534A1 (fr) 2007-10-25
WO2007119029A2 (fr) 2007-10-25
US20090233941A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
WO2007098281A3 (fr) Composés oxystérols et voie
NI201000055A (es) 2&#39; - fluoro - 2&#39; - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
WO2006124748A3 (fr) Composes polycycliques et procedes pour les utiliser
BRPI0619153A8 (pt) derivados de 4-aminopirroltriazina substituída, e composição farmacêutica
WO2008021851A3 (fr) Nouveaux composés comme antagonistes ou agonistes inverses pour les récepteurs d&#39;opioïdes
TW200745003A (en) Novel compounds
WO2007127834A3 (fr) Compositions et leurs méthodes d&#39;élaboration
WO2007038138A3 (fr) Utilisation pharmaceutique de composes amido
CL2007001882A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
WO2009156462A3 (fr) Composés organiques
WO2008013838A3 (fr) Dérivés de pyridizinone
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
NO20091509L (no) Substituerte tetrahydropyrrolopyrazinforbindelser med affinitet KCNQ2/3 K+ kanal og anvendelse derav i medikamenter
WO2009137391A3 (fr) Composés de benzène sulfonamide thiazole et oxazole
CL2007001881A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
WO2007052023A3 (fr) Composes
UY31145A1 (es) Derivado de 17b+ciano-18a-homo-19-nor-androst-4-eno, su uso y medicamento que lo contiene
HN2008001720A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
WO2007141392A3 (fr) Compositions comprenant de l&#39;acide bétulonique
TW200630336A (en) Novel compounds
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
TW200621690A (en) Novel compounds
CL2007002377A1 (es) Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2650534

Country of ref document: CA

Ref document number: 2007731905

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07731905

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12226418

Country of ref document: US